Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- VICO.ST
- Price
- 6.40
- Stock movement down
- -0.10 (-1.54%)
- Company name
- Vicore Pharma Holding AB (publ)
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.50B
- Ent value
- 1.19B
- Price/Sales
- 14.40
- Price/Book
- 3.97
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 27.72%
- 1 year return
- -63.82%
- 3 year return
- -36.05%
- 5 year return
- -12.60%
- 10 year return
- -
Last updated: 2025-04-12
DIVIDENDS
VICO.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 14.40 |
| Price to Book | 3.97 |
| EV to Sales | 11.45 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 234.58M |
| EPS (TTM) | -1.76 |
| FCF per share (TTM) | -3.85 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 104.24M |
| Gross profit (TTM) | 51.45M |
| Operating income (TTM) | -217.50M |
| Net income (TTM) | -196.45M |
| EPS (TTM) | -1.76 |
| EPS (1y forward) | -1.76 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 49.35% |
| Operating margin (TTM) | -208.65% |
| Profit margin (TTM) | -188.45% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 336.62M |
| Net receivables | 2.20M |
| Total current assets | 406.90M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 406.90M |
| Accounts payable | 12.43M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 28.52M |
| Total liabilities | 29.16M |
| Shareholder's equity | 377.74M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -181.24M |
| Capital expenditures (TTM) | 248.60M |
| Free cash flow (TTM) | -429.84M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -52.01% |
| Return on Assets | -48.28% |
| Return on Invested Capital | -52.01% |
| Cash Return on Invested Capital | -113.79% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 6.55 |
| Daily high | 6.60 |
| Daily low | 6.09 |
| Daily Volume | 465K |
| All-time high | 36.58 |
| 1y analyst estimate | 34.03 |
| Beta | 0.63 |
| EPS (TTM) | -1.76 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 1 May 2025 |
Downside potential
Loading...
Downside potential data
| VICO.ST | S&P500 | |
| Current price drop from All-time high | -82.51% | -12.89% |
| Highest price drop | -82.70% | -56.47% |
| Date of highest drop | 9 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -39.90% | -11.07% |
| Avg time to new high | 56 days | 12 days |
| Max time to new high | 1084 days | 1805 days |
COMPANY DETAILS
Marketcap
1.50B
Marketcap category
Small-cap
Description
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases. It develops C21, an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. The company is also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis. Vicore Pharma Holding AB (publ) has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor, as well as a collaboration and development agreement with Alex Therapeutics AB to develop a digital app in interstitial lung diseases, such as IPF. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.
Employees
29
Website
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
STOCKHOLM, SE / ACCESS Newswire / March 28, 2025 /Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announ...
March 28, 2025
STOCKHOLM, SE / ACCESS Newswire / March 26, 2025 / Vicore Pharma Holding (STO:VICO) The shareholders of Vicore Pharma Holding AB (publ), Reg. No. 556680-3804 ("Vicore Pharma" or the "company"), with i...
March 26, 2025
STOCKHOLM, SE / ACCESS Newswire / March 26, 2025 /Vicore Pharma Holding (STO:VICO) Stockholm, March 26, 2025 - Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, a...
March 26, 2025
STOCKHOLM, SWEDEN / ACCESS Newswire / February 27, 2025 / Vicore Pharma Holding (STO:VICO) Stockholm, February 27, 2025 - Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a n...
February 27, 2025
STOCKHOLM, SWEDEN / ACCESS Newswire / February 26, 2025 / Vicore Pharma Holding (STO:VICO) Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2...
February 26, 2025
STOCKHOLM, SE / ACCESSWIRE / May 31, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 31, 2024 - Vicore Pharma Holding AB (STO: VICO) ("Vicore") announced today that the number of Vicore shares ...
May 31, 2024
STOCKHOLM, SWEDEN / ACCESSWIRE / May 20, 2024 / Vicore Pharma Holding (STO:VICO) Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment. The therapy w...
May 20, 2024
STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential ...
May 14, 2024
STOCKHOLM, SE / ACCESSWIRE / May 7, 2024 / Vicore Pharma Holding (STO:VICO) The following resolutions were passed at the annual general meeting (the "AGM") of Vicore Pharma Holding AB (publ) on 7 May ...
May 7, 2024
STOCKHOLM, SWEDEN / ACCESSWIRE / May 3, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 3 2024- Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a new class of drug ca...
May 3, 2024